Learn more about our commitment to a sustainable future Discover how we champion inclusion and diversity at AstraZeneca We have 199 projects in our pipeline View pipeline Learn about our cell therapy ambition The Discovery Centre in Cambridge (UK) is one of our global science centres ...
Try to address your concerns with your manager, HR or Local Compliance Assurance. You can also submit a report to AZethics through web-submission or telephone in multiple languages. Please click above links to report a concern online or via telephone. What happens if I report a concern via ...
21 new molecular entities in our late-stage pipeline 3 new molecular entities under review Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets...
There was a strong trend towards improved overall survival (OS) with ENHERTU (HR 0.56; 95% CI 0.36-0.86; nominal p=0.007172), however this analysis is not yet mature and is not statistically significant. Nearly all patients treated wi...
Scientist(在职员工)-Uk-2020年10月14日 Big pharma.Benefits good, pay good, management mainly driven by their own promotion prospects.Science follows what is fashionable, so not a lot of continuity. 优点 Flexible working 缺点 Management 这篇点评对您有用吗?
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 ...
In patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (...
AstraZeneca has a comprehensive portfolio of approved and promising compounds in development that leverage different mechanisms of action to address the biologically diverse breast cancer tumour environment. AstraZeneca aims to continue to transform outcomes for HR-positive breast cancer with foundational med...
AstraZeneca aims to continue to transform outcomes for HR-positive breast cancer with foundational medicines FASLODEX and ZOLADEX and the next-generation oral SERD and potential new medicine camizestrant. PARP inhibitor LYNPARZA is ...
potential in HR-positive and triple-negative breast cancer AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, 2022. Twelve AstraZeneca medicines...